Abstract :
[en] This review discusses the underexploited potential of renewable glycerol and its derivatives for the preparation of active pharmaceutical ingredients, some of which are on the World Health Organization list of essential medicines. The regulatory challenges faced by industries regarding the replacement of petro-based building blocks with renewably sourced ones are described before diving into pharmaceutical ingredients that could potentially incorporate these bio-based atoms. The active pharmaceutical ingredients (APIs) are sorted by their therapeutical potential, including entities treating cardiovascular diseases, musculoskeletal drugs and compounds endowed with anti-infective properties. Finally, polymeric drugs and more eclectic substrates such as dietary supplements, radiosensitizers or chemotherapeutical agents are considered in the last two sub-sections. The broad spectrum of presented substrates relying on glycerol or potentially glycerol-derived reagents in their synthetic pathway emphasizes the potential contribution of bio-based substrates in already developed industrial processes. The examples in this review hint toward a future chemical development in which APIs may be constructed with increasing percentages of bio-sourced atoms.
Funding text :
The authors acknowledge the Interreg V-A Euregio Meuse-Rhine (EMR) program (IN FLOW) for funding. IN FLOW was granted a \u20AC 2.1 M total budget from the European Regional Development Fund (ERDF). With the investment of EU funds in Interreg projects, the European Union directly invests in economic development, innovation, territorial development, social inclusion and education in the Euregio Meuse-Rhine. The authors also thank the University of Li\u00E8ge and the F.R.S.-FNRS (Incentive grant for scientific research MIS F453020F, J. C. M. M.). The authors also thank Dr Pierre Francotte (ULi\u00E8ge, Department of Pharmacy), Dr Damien Cornut (Mithra Pharmaceuticals), Dr Laurent Provins (UCB Pharma), Dr Jean Fournier (Oril Industrie), Maryse Phan (Oril Industrie) and the EMA Pharmaceutical Quality Office for their answers related to the regulatory aspects. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.
Scopus citations®
without self-citations
1